



SYNformulas
A Global Leader in Probiotics

Company portrait

SYNformulas is a globally leading probiotics company focused on researching the human microbiome and developing breakthrough, evidence-based probiotics that significantly improve the quality of life. Under the brand Kijimea® the company's medical products, nutritional supplements and products for supplementary balanced diets are sold in ten countries on a pharmacy-exclusive basis.

SYNformulas achieved a breakthrough in the treatment of Irritable Bowel Syndrome: In two independent studies the patented bacterial strain *B. bifidum* MIMBb75, which is used for the products Kijimea® IBS and Kijimea® IBS PRO, showed significant efficacy in the widespread disease Irritable Bowel Syndrome and was most recently included in the S3 guideline Irritable Bowel Syndrome.

For its pioneering product development with clinically proven efficacy, the company relies on an expert research & development team as well as cooperation with a broad network of internationally recognised researchers and universities.

SYNformulas is based in Gräfelfing close to Munich and is a subsidiary of the healthcare incubator FUTRUE, which operates internationally with over 20 companies.